|
PT2069336E
(pt)
|
2006-09-07 |
2013-03-07 |
Actelion Pharmaceuticals Ltd |
Derivados de piridin-4-ilo como agentes imunomoduladores
|
|
BRPI0808789A2
(pt)
|
2007-03-16 |
2014-08-12 |
Actelion Pharmaceuticals Ltd |
Compostos e composição farmacêutica de derivados aminopiridina e uso destes
|
|
PT2195311E
(pt)
|
2007-08-17 |
2011-05-25 |
Actelion Pharmaceuticals Ltd |
Derivados de piridina como moduladores do receptor s1p1/edg1
|
|
KR20100092473A
(ko)
|
2007-11-01 |
2010-08-20 |
액테리온 파마슈티칼 리미티드 |
신규한 피리미딘 유도체
|
|
MX2010005889A
(es)
|
2007-12-10 |
2010-06-22 |
Actelion Pharmaceuticals Ltd |
Derivados de tiofeno como agonistas de s1p1/edg1.
|
|
CA2715317A1
(en)
|
2008-03-07 |
2009-09-11 |
Actelion Pharmaceuticals Ltd |
Novel aminomethyl benzene derivatives
|
|
EP3782991A1
(en)
|
2008-05-14 |
2021-02-24 |
The Scripps Research Institute |
Novel modulators of sphingosine phosphate receptors
|
|
EP2687513B1
(en)
|
2008-06-09 |
2020-12-02 |
Ludwig-Maximilians-Universität München |
Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
|
|
UY31922A
(es)
*
|
2008-06-20 |
2010-01-05 |
Glaxo Group Ltd |
Compuestos
|
|
US8580841B2
(en)
|
2008-07-23 |
2013-11-12 |
Arena Pharmaceuticals, Inc. |
Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
|
|
HRP20160890T1
(hr)
|
2008-08-27 |
2016-09-23 |
Arena Pharmaceuticals, Inc. |
Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja
|
|
ES2405054T3
(es)
|
2009-01-23 |
2013-05-30 |
Bristol-Myers Squibb Company |
Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
|
|
WO2010085582A1
(en)
|
2009-01-23 |
2010-07-29 |
Bristol-Myers Squibb Company |
Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
|
|
JP2012515787A
(ja)
|
2009-01-23 |
2012-07-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
|
|
CA2767585C
(en)
|
2009-07-16 |
2017-09-26 |
Actelion Pharmaceuticals Ltd |
Pyridin-4-yl derivatives
|
|
US8399451B2
(en)
|
2009-08-07 |
2013-03-19 |
Bristol-Myers Squibb Company |
Heterocyclic compounds
|
|
ES2665461T3
(es)
*
|
2009-11-13 |
2018-04-25 |
Celgene International Ii Sàrl |
Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral
|
|
MX2012005560A
(es)
*
|
2009-11-13 |
2012-10-05 |
Receptos Inc |
Moduladores selectivos del receptor de esfingosina 1 fosfato y metodos de sintesis quiral.
|
|
AU2015202660B2
(en)
*
|
2009-11-13 |
2016-10-27 |
Receptos Llc |
Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
|
|
PH12012500940B1
(en)
*
|
2009-11-13 |
2018-09-26 |
Receptos Llc |
Selective heterocyclic sphingosine 1 phosphate receptor modulators
|
|
JP5856980B2
(ja)
|
2010-01-27 |
2016-02-10 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
|
|
CN105503882B
(zh)
|
2010-03-03 |
2019-07-05 |
艾尼纳制药公司 |
制备s1p1受体调节剂及其晶体形式的方法
|
|
EP2390252A1
(en)
*
|
2010-05-19 |
2011-11-30 |
Almirall, S.A. |
New pyrazole derivatives
|
|
EP2619190B1
(en)
*
|
2010-09-24 |
2015-08-12 |
Bristol-Myers Squibb Company |
Substituted oxadiazole compounds and their use as s1p1 agonists
|
|
MA34910B1
(fr)
|
2011-01-19 |
2014-02-01 |
Actelion Pharmaceuticals Ltd |
Dérivés de 2-methoxy-pyridin-4-yl
|
|
WO2012118935A1
(en)
|
2011-03-03 |
2012-09-07 |
Proteotech Inc |
Compounds for the treatment of neurodegenerative diseases
|
|
CN102718726A
(zh)
*
|
2011-03-31 |
2012-10-10 |
上海铂力生物科技有限公司 |
作为免疫调节剂的(z)-5-苯亚甲基噻唑啉-4-酮衍生物
|
|
US9481659B2
(en)
|
2011-05-13 |
2016-11-01 |
Celgene International Ii Sàrl |
Selective heterocyclic sphingosine 1 phosphate receptor modulators
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
US9199975B2
(en)
|
2011-09-30 |
2015-12-01 |
Asana Biosciences, Llc |
Biaryl imidazole derivatives for regulating CYP17
|
|
EP2822931B1
(en)
|
2012-03-09 |
2017-05-03 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
SG11201504622PA
(en)
|
2012-12-20 |
2015-07-30 |
Inception 2 Inc |
Triazolone compounds and uses thereof
|
|
PT2958913T
(pt)
|
2013-02-20 |
2018-12-03 |
Lg Chemical Ltd |
Agonistas de recetores de esfingosina-1-fosfato, métodos para a sua preparação e composições farmacêuticas que os contêm como agente ativo
|
|
NZ713080A
(en)
*
|
2013-03-15 |
2020-06-26 |
Idorsia Pharmaceuticals Ltd |
Pyridin-4-yl derivatives
|
|
CN105579440A
(zh)
|
2013-09-06 |
2016-05-11 |
因森普深2公司 |
三唑酮化合物及其应用
|
|
EP2853532B1
(en)
*
|
2013-09-28 |
2020-12-09 |
Instytut Farmakologii Polskiej Akademii Nauk |
1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
|
|
WO2015066515A1
(en)
*
|
2013-11-01 |
2015-05-07 |
Receptos, Inc. |
Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
|
|
WO2015196258A1
(en)
*
|
2014-06-26 |
2015-12-30 |
Monash University |
Enzyme interacting agents
|
|
PL3242666T3
(pl)
|
2015-01-06 |
2025-02-17 |
Arena Pharmaceuticals, Inc. |
Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
|
|
EP3280703A1
(en)
|
2015-04-06 |
2018-02-14 |
Auspex Pharmaceuticals, Inc. |
Deuterium-substituted oxadiazoles
|
|
PH12017502097B1
(en)
|
2015-05-20 |
2023-05-05 |
Idorsia Pharmaceuticals Ltd |
Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
|
|
BR112017027656B1
(pt)
|
2015-06-22 |
2023-12-05 |
Arena Pharmaceuticals, Inc. |
Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
|
|
EP4566676A3
(en)
|
2016-06-14 |
2025-11-05 |
Receptos LLC |
Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
|
|
CN109563059A
(zh)
|
2016-08-19 |
2019-04-02 |
苏州科睿思制药有限公司 |
奥扎莫德的晶型及其制备方法
|
|
WO2018050091A1
(zh)
|
2016-09-14 |
2018-03-22 |
苏州科睿思制药有限公司 |
奥扎莫德盐酸盐的晶型及其制备方法
|
|
KR102408814B1
(ko)
|
2016-09-29 |
2022-06-14 |
리셉토스 엘엘씨 |
루푸스를 치료하기 위한 화합물 및 방법
|
|
EP3570740B1
(en)
|
2017-01-23 |
2023-08-30 |
Naqi Logix Inc. |
Apparatus and method for using imagined direction to perform at least one action
|
|
MX2019009843A
(es)
|
2017-02-16 |
2020-01-30 |
Arena Pharm Inc |
Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
|
|
MX2019009841A
(es)
|
2017-02-16 |
2020-01-30 |
Arena Pharm Inc |
Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
|
|
CN110325517B
(zh)
*
|
2017-02-28 |
2021-03-02 |
南京明德新药研发有限公司 |
螺环类化合物及其应用
|
|
WO2018211323A1
(en)
*
|
2017-05-17 |
2018-11-22 |
Oppilan Pharma Ltd. |
Hetercyclic compounds for the treatment of disease
|
|
EP3677575A4
(en)
|
2017-08-31 |
2020-07-15 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR
|
|
WO2019094409A1
(en)
|
2017-11-07 |
2019-05-16 |
Teva Pharmaceuticals International Gmbh |
Salts and solid state forms of ozanimod
|
|
CA3102136A1
(en)
|
2018-06-06 |
2019-12-12 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the s1p1 receptor
|
|
CN112955431A
(zh)
|
2018-09-06 |
2021-06-11 |
艾尼纳制药公司 |
可用于治疗自身免疫性病症和炎性病症的化合物
|
|
AR116479A1
(es)
|
2018-09-25 |
2021-05-12 |
Quim Sintetica S A |
Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
|
|
WO2020152718A1
(en)
|
2019-01-25 |
2020-07-30 |
Mylan Laboratories Limited |
Polymorphic forms 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyethyl) amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile
|
|
KR20220007065A
(ko)
*
|
2019-04-26 |
2022-01-18 |
리셉토스 엘엘씨 |
스핑고신 1 포스페이트 수용체 조절인자
|
|
CN112062785B
(zh)
*
|
2019-06-11 |
2023-06-27 |
广东东阳光药业有限公司 |
奥扎莫德及其中间体的制备方法
|
|
WO2021026479A1
(en)
*
|
2019-08-07 |
2021-02-11 |
Stamford, Andrew |
Small molecule inhibitors of s1p2 receptor and uses thereof
|
|
MX2022007376A
(es)
|
2019-12-20 |
2022-09-02 |
Tenaya Therapeutics Inc |
Fluoroalqull-oxadiazoles y sus usos.
|
|
KR20220158745A
(ko)
*
|
2020-03-27 |
2022-12-01 |
리셉토스 엘엘씨 |
스핑고신 1 포스페이트 수용체 조절제
|
|
EP4126827B1
(en)
*
|
2020-03-27 |
2024-11-20 |
Receptos LLC |
Sphingosine 1 phosphate receptor modulators
|
|
EP4126829B1
(en)
|
2020-03-27 |
2026-02-18 |
Receptos LLC |
Sphingosine 1 phosphate receptor modulators
|
|
WO2021207051A1
(en)
*
|
2020-04-06 |
2021-10-14 |
Bristol-Myers Squibb Company |
Methods of treating acute respiratory disorders
|
|
US20230233532A1
(en)
*
|
2020-06-26 |
2023-07-27 |
The Penn State Research Foundation |
Sphingosine-1-phosphate receptor 1 agonist and liposomal formulations thereof
|
|
AU2021325872A1
(en)
*
|
2020-08-10 |
2023-03-16 |
Dana-Farber Cancer Institute, Inc. |
Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
|
|
US20240252502A1
(en)
|
2021-05-04 |
2024-08-01 |
Tenaya Therapeutics, Inc. |
Hdac6 inhibitors for treatment of metabolic disease and hfpef
|
|
WO2023152767A1
(en)
|
2022-02-11 |
2023-08-17 |
Mylan Laboratories Limited |
Polymorphic forms of ozanimod hydrochloride
|
|
WO2024117172A1
(ja)
|
2022-11-30 |
2024-06-06 |
花王株式会社 |
痒みの予防又は改善剤
|
|
EP4720047A1
(en)
|
2023-05-31 |
2026-04-08 |
Química Sintética, S.A. |
Amorphous and crystalline form of ozanimod hydrochloride
|
|
CN119320366B
(zh)
*
|
2023-07-17 |
2025-11-18 |
中国医学科学院药物研究所 |
取代萘甲基噁二唑-苯胺类化合物及其用途
|
|
US11905265B1
(en)
*
|
2023-10-13 |
2024-02-20 |
King Faisal University |
3,4-dimethoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2ylthio)acetoxy)benzimidamide as an antimicrobial compound
|
|
WO2025083549A1
(en)
|
2023-10-16 |
2025-04-24 |
Sun Pharma Advanced Research Company Limited |
Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
|
|
TW202535949A
(zh)
|
2023-12-20 |
2025-09-16 |
美商必治妥美雅史谷比公司 |
靶向IL-18受體β(IL-18RB)之抗體及相關方法
|